Tele-Coaching Intervention to Improve Treatment Adherence in Cystic Fibrosis

Inclusion Criteria: COACH Participants: 1\. Be a CF-focused clinician employed by one of the study sites, including: social workers; respiratory therapists, pharmacists, nurse practitioners, nurses, mental health coordinators, dieticians, and psychologists. PATIENT Participants: 1. Male or female ≥ 14 and ≤ 25 years of age; 2. Documentation of a CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and one or more of the following criteria: (a) sweat chloride \> 60 mEq/L by quantitative pilocarpine iontophoresis test (QPIT), and/or (b) two well-characterized mutations in the CFTR (cystic fibrosis transmembrane conductance regulator) gene; 3. Has been prescribed one or more respiratory nebulized medications, such as: (a) dornase alfa, (b) hypertonic saline, (c) inhaled tobramycin, (d) inhaled aztreonam, (e) inhaled colistimethate \*and/or\* uses a vest device for airway clearance; 4. If taking, or anticipating to start on, Trikafta, has been taking the modulator for 6 weeks prior to enrolling in the study; 5. Has access to necessary resources for participating in a technology-based intervention: (a) mobile phone, tablet, computer, or digital camera capable of capturing and sending a digital image, and access to Internet; (b) an email account; 6. Is English-speaking; 7. Endorsed score of ≥3 on any treatment component on the CF-CBS at Enrollment Visit. CAREGIVER Participants: 1. Is a caregiver of and resides with a Patient Participant in this study; 2. Has received permission from the Patient Participant, if aged 18 years of age or older, to be in the study; and 3. Is English-speaking. Exclusion Criteria: COACH Participants: 1. Anticipated change in CF Center during study period; 2. Physicians (MD, DO, or equivalent degree); 3. Advanced practice providers (e.g., APRN, PA) who serve as the primary provider in the CF clinic setting; and 4. Site research coordinator designated for this study. PATIENT Participants: 1. Participation in the previous Tele-coaching study; 2. Anticipated transition to another CF care center within study period; 3. Planned or scheduled hospitalization between consent and start of intervention; 4. Self-reported current or planned pregnancy; 5. Having a person in the same household who is also enrolled in the study; 6. Presence of a condition, abnormality, or other factor that, in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data including, but not limited to: (a) diagnosis of intellectual or developmental disability that would preclude safe or adequate completion of measures; (b) history of, or planned, lung transplant; 7. Participation in concurrent studies targeting improvement in treatment adherence. CAREGIVER Participants: 1. Participation in the previous Tele-coaching study; 2. Only one caregiver per Patient Participant can be enrolled in the Caregiver Cohort.